Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Figure 2

Forest plot of the overall meta-analysis results in the randomized clinical trials. Comparison of (a) the forced vital capacity (FVC) and (b) the diffusing capacity for carbon monoxide (DLCO) at 12 months for patients with scleroderma lung disease treated with cyclophosphamide versus a control group. See Table 2 for study details. RCT, randomized clinical trial; SE, standard error; CI, confidence interval; Chi2, chi-squared; df, degree of freedom; I2, I-squared; Z, Z value; Mean difference, weighted mean difference; Random, random-effects model.

Back to article page